The efficacy of the dopamine D2/D3 antagonist tiapride in maintaining abstinence: A randomized, double-blind, placebo-controlled trial in 299 alcohol-dependent patients

International Journal of Neuropsychopharmacology

Volumn 10, Issue 5, 2007, Pages 653-660

  Bender, Stefan ^a,e   Scherbaum, Norbert ^a   Soyka, Michael ^b   Rüther, Eckart ^c   Mann, Karl ^d   Gastpar, Markus ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e Westfalische Klinik Marsberg   (Germany)

Author keywords

Abstinence; Alcohol dependence; Dopamine antagonist; Placebo controlled trial; Tiapride

Indexed keywords

DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; PLACEBO; TIAPRIDE; DOPAMINE RECEPTOR BLOCKING AGENT;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; BLOOD PRESSURE VARIABILITY; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETOXIFICATION; DOPAMINERGIC SYSTEM; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART RATE VARIABILITY; HUMAN; HYPERPROLACTINEMIA; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT SELECTION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOPHRENIA; SIDE EFFECT; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; WERNICKE KORSAKOFF SYNDROME; AGED; DEMOGRAPHY; MIDDLE AGED; TIME;

ADULT; AGED; ALCOHOLISM; DEMOGRAPHY; DOPAMINE ANTAGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; TIAPRIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 34948816067     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145706007164     Document Type: Article

References (31)

1. Babor TF, Steigberg K, Anton R, Del Boca F (2000). Talk is cheap: measuring drinking outcomes in clinical trials. Journal of Studies on Alcohol 61, 55-63.
2. Berridge KC, Robinson TE (1998). What is the role of dopamine in reward hedonic impact, reward learning, or incentive salience? Brain Research Reviews 28, 309-369.
3. Cohen C, Perrault G, Sanger DJ (1998). Preferential involvement of D3 versus D2 dopamine receptors in the effects of dopamine receptor ligands on oral ethanol self-administration in rats. Psychopharmacology 140, 478-485.
4. Collegium Internationale Psychiatriae Scalarum (1996). Internationale Skalen für Psychiatrie (4th edn). Göttingen: Beltz.
5. Delamaire D, Carpentier MC, Eudier F, Derouet J, Bourel M (1986). Trial of tiapride in patients discharged after hospitalization for alcohol withdrawal: a randomized, double-blind trial in fifty-one patients with alcohol-related lives disease [in French]. La Semaine des Hôpitaux: Organe Fondé par l'Association d'Enseignement Médical des Hôpitaux de Paris 62, 3109-3114.
6. Di Chiara G, Imperato A (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proceedings of the National Academy of Sciences USA 85, 5274-5278.
7. Dose M, Lange HW (2000). The benzamide tiapride: treatment of extrapyramidal motor and other clinical syndromes. Pharmacopsychiatry 33, 19-27.
8. Franken IH, Booij J, van den Brink W (2005). The role of dopamine in human addiction: from reward to motivated attention. European Journal of Pharmacology 526, 199-206.
9. Franz M, Dlabal H, Kunz S, Ulferts J, Gruppe H, Gallhofer B (2001). Treatment of alcohol withdrawal: tiapride and carbamazepine versus clomethiazol. A pilot study. European Archives of Psychiatry and Clinical Neuroscience 251, 185-192.
10. Garcia-Ledona FJ, Cox BF (2003). BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine addiction. CNS Drug Reviews 9, 141-158.
11. Grace AA (2000). The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction 95 (Suppl. 2), S119-S128.
12. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology (revised). Rockville, MD: U.S. National Institute of Health, Psychopharmacology Research Branch.
13. Jacobi C, Brand-Jacobi J, Marquardt F (1987). The 'Göttinger Abhängigkeitsskala (GABS)': an instrument for the differential assessment of the severity of alcohol dependence [in German]. Suchtgefahren 33, 23-36.
14. Lucht M, Kuehn KU, Armbruster J, Abraham G, Gaensicke M, Barnow S, Tretzel H, Freyberger HJ (2003). Alcohol withdrawal treatment in intoxicated vs. non-intoxicated patients: a controlled open-label study with tiapride/carbamazepine, clomethiazole and diazepam. Alcohol and Alcoholism 38, 168-175.
15. Mann K, Lehert P, Morgan MY (2004). The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcoholism, Clinical and Experimental Research 28, 51-63.
16. Modell JG, Mountz JM, Glaser FB, Lee JY (1993). Effect of haloperidol on measures of craving and impaired control in alcoholic subjects. Alcoholism, Clinical and Experimental Research 17, 234-240.
17. Naranjo CA, Dongier M, Bremner KE (1997). Long-acting injectable bromocriptine does not reduce relapse in alcoholics. Addiction 92, 969-978.
18. Noble EP (1996). Alcoholism and the dopaminergic system: a review. Addiction Biology 1, 333-348.
19. Peters DH, Faulds D (1994). Tiapride - a review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs 47, 1010-1032.
20. Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, Sokoloff P (1999). Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 400, 371-375.
21. Rommelspacher H, Raeder C Kaulen P, Bruning G (1992). Adaptive changes of dopamine-D2 receptors in rat brain following ethanol withdrawal: a quantitative autoradiographic investigation. Alcohol 9, 355-362.
22. Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, Porsolt R (2001). The preclinical pharmacologic profile of tiapride. European Psychiatry 16 (Suppl. 1), 29s-34s.
23. Schmidt LG, Kuhn S, Smolka M, Schmidt K, Rommelspacher H (2002). Lisuride, a dopamine D2 receptor agonist, and anticraving drug expectancy as modifiers of relapse in alcohol dependence. Progress in Neuro- Psychopharmacology and Biological Psychiatry 26, 209-217.
24. Shaw GK, Makumdar SK, Waller S, MacGarvie J, Dunn G (1987). Tiapride in the long-term management of alcoholics of anxious or depressive temperament. British Journal of Psychiatry 150, 164-168.
25. Shaw GK, Waller S, Majumdar SK, Alberts JL, Latham CJ, Dunn G (1994). Tiapride in the prevention of relapse in recently detoxified alcoholics. British Journal of Psychiatry 165, 515-523.
26. Soyka M, Morhart-Klute V, Horak M (2002). A combination of carbamazepine/tiapride in outpatient alcohol detoxification. Results from an open clinical study. European Archives of Psychiatry and Clinical Neuroscience 252, 197-200.
27. Soyka M, Schmidt F, Schmidt P (2006). Efficacy and safety of outpatient alcohol detoxification with a combination of tiapride/carbamazepine: additional evidence. Pharmacopsychiatry 39, 30-34.
28. Spanagel R, Weiss F (1999). The dopamine hypothesis of reward: past and current status. Trends in Neurosciences 22, 521-527.
29. Volkow ND, Fowler JS, Wang GJ (2003). Positron emission tomography and single-photon emission computed tomography in substance use research. Seminars in Nuclear Medicine 33, 114-128.
30. Wiesbeck GA, Weijers HG, Lesch OM, Glaser T, Toennes PJ, Boening J (2001). Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. Alcohol and Alcoholism 36, 329-334.
31. Wolffgramm J, Galli G, Thimm F, Heyne A (2000). Animal models of addiction: models for therapeutic strategies? Journal of Neural Transmission 107, 649-668.